-The Business Standard Having quit the National Advisory Council (NAC), Aruna Roy of the Mazdoor Kisan Sangharsh Samiti (MKSS) will intensify the movement to get minimum wages countrywide under the Mahatma Gandhi National Rural Employment Guarantee Act and a Rs 1,000 a month pension for unorganised labourers. She will also press the government to make it mandatory to have a pre-legislation process for all bills that the government proposes to introduce...
More »SEARCH RESULT
Total Matching Records found : 1587
Fast-track BPL status for 4 million families in Maoist zone -Subodh Ghildiyal
-The Times of India NEW DELHI: Four million households in Maoist-affected districts are likely to get BPL status without having to wait for another two years when the Socio-Economic Caste Census is expected to be completed. The list of BPL will be revised based on the findings of the census. The shortcut inclusion in the 82 Maoist-affected districts is aimed at making the poor, who fell between the cracks of the poverty...
More »Aruna Roy, social activist and NCPRI member interviewed by Pallavi Polanki
-Firstpost.com After the UPA-II released its self-congratulatory 79-page ‘Report card to the People', National Advisory Council (NAC) member and leading social activist Aruna Roy has come down heavily on the government for its poor performance in the social sector. Roy, an instrumental force behind the Right to Information Act, criticised the government for stalling on essential legislations such as the Food Security Bill, the Land Acquisition Bill and the Lokpal Bill. Roy spoke...
More »More trouble for Ranbaxy as drug boycott to continue
-The Business Standard After the US and Indian authorities, the medicines manufactured by Ranbaxy Laboratories are now under the scanner of hospitals, too. Mumbai's leading Jaslok Hospital has already put up a notice advising its doctors to avoid prescribing Ranbaxy drugs, while some others are reviewing the matter. Medanta Medicity officials say they will soon assess the situation and take a decision. "I have received around a dozen queries from patients recently....
More »USFDA scrutiny: Will pharma majors like Ranbaxy, Wockhardt be affected in long-term? -G Seetharaman
-The Economic Times Japanese companies do not mind erring on the side of caution. They are known to think longer and harder than their counterparts in other countries about big decisions, especially when it comes to entering a new market or acquiring a foreign company. But Japan's third biggest drugmaker Daiichi Sankyo would now wish it had spent more time doing due diligence on Ranbaxy Labs, in which it bought a...
More »
